Dupilumab in The Reactive Perforating Collagenosis Management in a Patient with Multimorbidity: A Case Report

EDEK Y. C., GÜLENGÜL M., ŞAHİN S., ÖĞÜT B., ADIŞEN E.

Turkish Journal of Dermatology, vol.19, no.4, pp.244-246, 2025 (ESCI, Scopus, TRDizin) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 4
  • Publication Date: 2025
  • Doi Number: 10.4274/tjd.galenos.2025.08760
  • Journal Name: Turkish Journal of Dermatology
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.244-246
  • Keywords: Acquired perforating dermatoses, dupilumab, reactive perforating collagenosis
  • Gazi University Affiliated: Yes

Abstract

Acquired perforating dermatoses (APD) are a group of diseases characterized by transepidermal excretion of dermal connective tissue materials and characterized by itchy skin lesions. Reactive perforating collagenosis (RPC) is the type of APD in which transepidermal collagen fiber elimination is detected. The number of cases in which dupilumab has been successfully used in the treatment of RPC is increasing in the literature. There are case reports showing the safe and effective use of dupilumab in RPC patients with comorbidities such as chronic kidney disease, Wilson disease, coronary artery disease, cerebrovascular disease, and hepatocellular cancer. In this case report, we present a female RPC patient with multimorbidity who had complete treatment response with dupilumab.